Artemis DNA, Inc., a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and diagnostic testing that enables "personalized" medicine through early disease detection, proudly announced today that they will be opening their first international location at 253A Hoang Sa, Phuong Da Kao, Quan 1 in Ho Chi Minh City, Vietnam.  Starting April 2022, Artemis DNA will begin offering its genetic tes

VenusP-ValveTM, Venus Medtech's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, received CE marking under the Medical Devices Regulation (MDR) to be marketed in Europe. Designed to treat patients with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract (RVOT) stenosis, VenusP-ValveTM is the first Chinese-made artificial heart valve approved in Europe, marking a new milestone in the global presence of China's

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the expansion of its in vivo imaging portfolio with the launch of the Vega® imaging system, a first-of-its kind ultrasound platform that combines hands-free, automated technology with high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more. PerkinElmer is one of the leading providers of preclinical im

Saranas announced its Early Bird Bleed Monitoring System has received an Innovative Technology contract from Vizient, Inc., the nation’s largest member-driven health care performance improvement company. This contract was awarded based on the recommendation of Early Bird by hospital experts who serve on one of Vizient’s member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the health care industry. The Early Bird

Aspirion, a leader in technology-enabled healthcare revenue cycle management, announced today that it has combined with ARx, a trusted partner to hospital systems to help collect their more challenging reimbursements. As part of the announcement, the ARx team will continue to be led by CEO Bill Chace. The combination closed on March 22, 2022. Terms of the agreement were not disclosed. The addition of ARx will further reinforce Aspirion’s strong market position in aged accounts

OxfordVR has successfully automated psychological therapy in VR for patients with mental illness. Users are guided by a virtual coach instead of a real-life therapist, allowing the treatment to reach many more patients. It is the first time a digital therapeutic of any kind has successfully been shown to help patients with schizophrenia and mood disorders with psychotic symptoms. The technology, called gameChangeVRTM is a 6 week, automated, VR treatment that delivers cognitive behav

Enovis Corporation, an innovation-driven medical technology growth company formerly known as Colfax Corporation, announced today the completion of its previously announced separation (the “Separation”) of its fabrication technology business into an independent, publicly traded company, ESAB Corporation (“ESAB”) (NYSE: ESAB). Immediately following the Separation, Enovis effected its previously announced reverse stock split of all issued and outstanding shares of Enovis

Ra Medical Systems, Inc., a medical device company focusing on developing its excimer laser system to treat vascular diseases, announces the United States Patent and Trademark Office has granted the company a patent for liquid-filled laser ablation catheters with expanded distal optical windows. U.S. patent 11,284,941 (the ’941 patent), titled Laser Ablation Catheters Having Expanded Distal Tip Windows for Efficient Tissue Ablation, describes a catheter with an increased ablation surfac

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. announced that its mechanism-based 3CL protease inhibitors Tollovir® and Tollovid™ that target the active site of the 3CL protease showed robust inhibitory activity against the 3CL protease of the BA.1 and BA.2 strains of the Omicron SARS-CoV-2 variant of concern (VOC). Additionally, Tollovir and Tollovid showed inhibitory activi

Interrad Medical, a privately held medical device company, announces its SecurAcath device has received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country. The contract was based on the recommendation of SecurAcath by hospital experts in this category who serve on one of Vizient's member-led councils. Innovative Technology contracts are recommended after review and interaction with products s